WAP four-disulfide core domain protein 2 mediates the proliferation of human ovarian cancer cells through the regulation of growth- and apoptosis-associated genes

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 288-296

  Chen, Yao ^a   Mu, Xia ^a   Wang, Suihai ^a   Zhao, Liang ^b   Wu, Yingsong ^a,b   Li, Jiliang ^a,b,c   Li, Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apoptosis; Cell proliferation; Ovarian cancer; WAP four disulfide core domain protein 2

Indexed keywords

CASPASE 3; CYCLIN D1; FAS LIGAND; KI 67 ANTIGEN; SHORT HAIRPIN RNA; TUMOR MARKER; UNCLASSIFIED DRUG; WFDC2 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; WFDC2 GENE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIN D1; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84872832231     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2114     Document Type: Article

References (31)

1. Kobel M, Kalloger SE, Boyd N, et al: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232, 2008.
2. Bingle L, Singleton V and Bingle CD: The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 21: 2768-2773, 2002.
3. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63: 3695-3700, 2003.
4. Peters DG, Kudla DM, Deloia JA, et al: Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev 14: 1717-1723, 2005.
5. Galgano MT, Hampton GM and Frierson HF Jr.: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19: 847-853, 2006.
6. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH and Urban N: Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One 3: e2633, 2008.
7. Bingle L, Cross SS, High AS, et al: WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 7: 61, 2006.
8. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P and Revets H: Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 100: 5778-5782, 2003.
9. Clauss A, Lilja H and Lundwall A: A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J 368: 233-242, 2002.
10. Israeli O, Goldring-Aviram A, Rienstein S, Ben-Baruch G, Korach J, Goldman B and Friedman E: In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet 160: 35-42, 2005.
11. Hough CD, Cho KR, Zonderman AB, Schwartz DR and Morin PJ: Coordinately up-regulated genes in ovarian cancer. Cancer Res 61: 3869-3876, 2001.
12. Devoogdt N, Revets H, Kindt A, Liu YQ, De Baetselier P and Ghassabeh GH: The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor. J Immunol 177: 8046-8052, 2006.
13. Simpkins FA, Devoogdt NM, Rasool N, et al: The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells. Carcinogenesis 29: 466-472, 2008.
14. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D and Simmen FA: Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 277: 29999-30009, 2002.
15. Clauss A, Ng V, Liu J, et al: Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 12: 161-172, 2010.
16. Tremblay GM, Sallenave JM, Israél-Assayag E, Cormier Y and Gauldie J: Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am J Respir Crit Care Med 154: 1092-1098, 1996.
17. Taggart CC, Greene CM, McElvaney NG and O'Neill S: Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 277: 33648-33653, 2002.
18. Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC and McElvaney NG: Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 281: 34730-34735, 2006.
19. Drannik AG, Henrick BM and Rosenthal KL: War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem Soc Trans 39: 1427-1432, 2011.
20. Velarde MC, Parisek SI, Eason RR, Simmen FA and Simmen RC: The secretory leukocyte protease inhibitor gene is a target of epidermal growth factor receptor action in endometrial epithelial cells. J Endocrinol 184: 141-151, 2005.
21. Westin U, Nystrom M, Ljungcrantz I, Eriksson B and Ohlsson K: The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm 11: 7-12, 2002.
22. Scott A, Weldon S and Taggart CC: SLPI and elafin: multifunctional antiproteases of the WFDC family. Biochem Soc Trans 39: 1437-1440, 2011.
23. Cordes C, Hasler R, Werner C, et al: The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol 39: 185-191, 2011.
24. Barbieri F, Cagnoli M, Ragni N, Pedulla F, Foglia G and Alama A: Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer 75: 1263-1268, 1997.
25. Shigemasa K, Hu C, West CM, et al: p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 4: 95-102, 1997.
26. Frutuoso C, Silva MR, Amaral N, Martins I, De Oliveira C and De Oliveira HM: Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma. Acta Med Port 14: 277-283, 2001 (In Portuguese).
27. Kobel M, Turbin D, Kalloger SE, Gao D, Huntsman DG and Gilks CB: Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gynecol Pathol 30: 366-371, 2011.
28. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U and Torp SH: The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4: 444-453, 2011.
29. Wang S, Ma XY, Xia Y and Zhang LH: Expressions of Ki67, PCNA and mitotic index in ovarian epithelial tumors. Sichuan Da Xue Xue Bao Yi Xue Ban 41: 575-580, 2010 (In Chinese).
30. Ma XY, He FX, Wu SF, Lu YP and Ma D: Expression of survivin in ovarian epithelial carcinoma and its correlation with expression of Fas and FasL. Ai Zheng 23: 173-176, 2004 (In Chinese).
31. Fassl S, Leisser C, Huettenbrenner S, et al: Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNFalpha, FasL, TRAIL, or Myc. Oncogene 22: 8343-8355, 2003.